Literature DB >> 10913945

Hyperproinsulinemia is not a characteristic feature in the offspring of patients with different phenotypes of type II diabetes.

I K Vauhkonen1, L K Niskanen, L Mykkänen, S M Haffner, M I Uusitupa, M Laakso.   

Abstract

OBJECTIVE: The purpose of this work was to study whether there are differences in plasma proinsulin levels and proinsulin-to-specific insulin ratio in the offspring of patients with different phenotypes of type II diabetes.
DESIGN: Eleven glucose-tolerant offspring of type II diabetic patients with deficient insulin secretion phenotype (IS group), nine glucose-tolerant offspring of patients with insulin-resistant phenotype (IR group), and fourteen healthy control subjects without a family history of diabetes were studied.
METHODS: Plasma specific insulin, plasma proinsulin, and plasma C-peptide levels were measured during a 2-h oral glucose tolerance test and during hyperglycemic clamp.
RESULTS: Plasma proinsulin levels during the oral glucose tolerance test and the hyperglycemic clamp did not differ among the study groups. The IR group had a lower fasting plasma proinsulin-to-specific insulin ratio (10.3+/-1.7%) than the control group (15.4+/-1.4%; P<0.05) and the IS group (18.6+/-2.7%; P<0.05). Furthermore, the IR group had lower plasma proinsulin-to-specific insulin ratio at 30, 60 and 90 min after the oral glucose load than the IS group. However, there were no significant differences in proinsulin-to-C-peptide ratio during the oral glucose tolerance test among the study groups. In stepwise multiple regression analysis, hepatic specific insulin extraction in the fasting state (beta =0.65; P<0.001) and fasting blood glucose (beta =0.32; P<0.05) together explained 52% of the variation in fasting plasma proinsulin-to-specific insulin ratio.
CONCLUSIONS: Hyperproinsulinemia is not a characteristic finding in glucose-tolerant offspring of type II diabetic probands with deficient insulin secretion or insulin-resistant phenotype. The differences in proinsulin-to-specific insulin ratios were most likely explained by different hepatic extraction among the study groups.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913945     DOI: 10.1530/eje.0.1430251

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  R C Loopstra-Masters; S M Haffner; C Lorenzo; L E Wagenknecht; A J Hanley
Journal:  Diabetologia       Date:  2011-09-30       Impact factor: 10.122

2.  Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes.

Authors:  Emily K Sims; Zunaira Chaudhry; Renecia Watkins; Farooq Syed; Janice Blum; Fangqian Ouyang; Susan M Perkins; Raghavendra G Mirmira; Jay Sosenko; Linda A DiMeglio; Carmella Evans-Molina
Journal:  Diabetes Care       Date:  2016-07-06       Impact factor: 19.112

3.  Both fasting and glucose-stimulated proinsulin levels predict hyperglycemia and incident type 2 diabetes: a population-based study of 9,396 Finnish men.

Authors:  Jagadish Vangipurapu; Alena Stančáková; Teemu Kuulasmaa; Johanna Kuusisto; Markku Laakso
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

4.  Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study.

Authors:  Aika Miya; Akinobu Nakamura; Hideaki Miyoshi; Shigekazu Ukawa; Koshi Nakamura; Takafumi Nakagawa; Yasuo Terauchi; Akiko Tamakoshi; Tatsuya Atsumi
Journal:  J Diabetes Investig       Date:  2020-03-01       Impact factor: 4.232

Review 5.  C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.

Authors:  Ernesto Maddaloni; Geremia B Bolli; Brian M Frier; Randie R Little; Richard D Leslie; Paolo Pozzilli; Raffaela Buzzetti
Journal:  Diabetes Obes Metab       Date:  2022-06-28       Impact factor: 6.408

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.